In the last trading session, 1.36 million Humacyte Inc. (NASDAQ:HUMA) shares changed hands as the company’s beta touched 1.06. With the company’s per share price at $3.05 changed hands at -$0.18 or -5.72% during last session, the market valuation stood at $345.26M. HUMA’s last price was a discount, traded about -83.61% off its 52-week high of $5.60. The share price had its 52-week low at $1.96, which suggests the last value was 35.74% up since then. When we look at Humacyte Inc.’s average trading volume, we note the 10-day average is 1.1 million shares, with the 3-month average coming to 707.89K.
Analysts gave the Humacyte Inc. (HUMA) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.80. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HUMA as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Humacyte Inc.’s EPS for the current quarter is expected to be -$0.25.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Humacyte Inc. (NASDAQ:HUMA) trade information
Instantly HUMA was in red as seen at the end of in last trading. With action -17.57%, the performance over the past five days has been red. The drop to weekly highs of 4.15 on Monday, 09/18/23 subtracted -5.72% to the stock’s daily price. The company’s shares are showing year-to-date upside of 44.55%, with the 5-day performance at -17.57% in the red. However, in the 30-day time frame, Humacyte Inc. (NASDAQ:HUMA) is -13.84% down. Looking at the short shares, we see there were 3.8 million shares sold at short interest cover period of 4.72 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7.42, meaning bulls need an upside of 58.89% from its current market value. According to analyst projections, HUMA’s forecast low is $3.50 with $16.00 as the target high. To hit the forecast high, the stock’s price needs a -424.59% plunge from its current level, while the stock would need to soar -14.75% for it to hit the projected low.
Humacyte Inc. (HUMA) estimates and forecasts
Data shows that the Humacyte Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 3.74% over the past 6 months, a -25.58% in annual growth rate that is considerably lower than the industry average of 11.90%. Year-over-year growth is forecast to reach -91.70% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $70k. 6 analysts are of the opinion that Humacyte Inc.’s revenue for the quarter ending Dec 2023 will be $70k. The company’s revenue for the corresponding quarters a year ago was $31k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 125.80%.
The 2023 estimates are for Humacyte Inc. earnings to increase by 54.80%.
HUMA Dividends
Humacyte Inc. is expected to release its next quarterly earnings report between November 08 and November 13.
Humacyte Inc. (NASDAQ:HUMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 39.70% of Humacyte Inc. shares while 12.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 19.97%. There are 12.04% institutions holding the Humacyte Inc. stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2023, the company held 4.16% of the shares, roughly 4.3 million HUMA shares worth $12.31 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 2.87% or 2.97 million shares worth $8.49 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.62 million shares estimated at $4.64 million under it, the former controlled 1.57% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.37% of the shares, roughly 1.41 million shares worth around $4.63 million.
